Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Pharmaceuticals


  • Pharma Analyst:  "PBM" Spells "Opportunity" Monday, 17 Nov 2008 | 8:12 AM ET

    Cost containment may spell trouble for much of the health-care sector, but Charles Boorady, healthcare providers analyst for Citigroup, says it's likely to spell success for pharmacy benefits managers.

  • Merck's Marketing Challenge: Gardasil For Guys Thursday, 13 Nov 2008 | 4:16 PM ET

    How in the world is Merck gonna rebrand a product it has spent so much time, effort and money gearing toward females so that males will use it, too? I'm not sure, but it'll be interesting to watch if or when MRK wins Food and Drug Administration approval of Gardasil for boys/young men.

  • Pharma And The Financial Crisis Thursday, 13 Nov 2008 | 11:11 AM ET
    Big Pharma

    Big pharma's got big problems. That should not come as news to anyone who works for, follows or invests in the industry.

  • Stick to US Stocks for Safety: BlackRock's Doll Wednesday, 12 Nov 2008 | 7:27 AM ET

    US stocks are a safer bet than their foreign counterparts now that the market has found a bottom, Bob Doll, CIO of global equities at BlackRock, told CNBC.

  • Clermont Wealth Strategies is 'underweight' the entire consumer discretionary sector, which includes retailers, Rob Morgan, market strategist at Clermont Wealth Strategies said.

  • "Boning Up" On Amgen's D-mab Friday, 7 Nov 2008 | 12:05 PM ET

    While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.

  • FDA Commissioner: Betting Starts On Who Obama Will Pick Wednesday, 5 Nov 2008 | 12:20 PM ET
    Barack Obama

    Even before the results of the election were official there was already speculation in the blogosphere about who might become the next Commissioner of the Food and Drug Administration under a President Obama.

  • AstraZeneca Beats Forecasts, Raises Year Guidance Thursday, 30 Oct 2008 | 1:51 PM ET

    Drugmaker AstraZeneca, helped by currency effects and cost savings, raised its full-year earnings forecasts on Thursday as third-quarter forecasts beat expectations.

  • Web Extra: Why U.S. Steel Earnings Don't Matter Monday, 27 Oct 2008 | 9:04 PM ET

    In this Web Extra the traders talk steel and pharma stocks while also paying some attention to the Fed meeting, housing numbers, and delivering a message to Bill Gates.

  • Opportunity Knocks: Pharma Stocks Thursday, 23 Oct 2008 | 9:13 AM ET

    Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.

  • Merck Shows "Sensitivity" Amid Massive Cuts Wednesday, 22 Oct 2008 | 10:56 AM ET
    Merck Earnings

    You gotta feel sorry for the folks at Merck. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the ax again.

  • Web Extra: Fast & Furious Trades For Wednesday Tuesday, 21 Oct 2008 | 7:24 PM ET

    In this Web Extra find out how the traders are playing Boeing, the release of Google's new phone, Ma' Bell earnings and more.

  • Roche Still Chasing Genentech Tuesday, 21 Oct 2008 | 1:28 PM ET

    Genentech investors who were hoping Roche would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed.

  • Earnings Roundup: PFE, DD, SGP, MMM, LMT, FITB Tuesday, 21 Oct 2008 | 8:55 AM ET

    U.S. companies ranging from chemicals like Du Pont, to pharmas like Pfizer and Schering Plough, and financials like Fifth Third and BlackRock, reported earnings Tuesday.

  • Game Plan: Merck Is Right for This Market Friday, 17 Oct 2008 | 7:04 PM ET

    A drug stock with a safe dividend? That's just what you need in this tough environment.

  • Readers Make Me Take My Medicine Friday, 17 Oct 2008 | 5:06 PM ET

    As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.

  • Lilly In The "Pink"--But Then Again Not Friday, 17 Oct 2008 | 10:57 AM ET
    Effient Ad

    I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.

  • Genentech-A-Go-Go: Our Lips Are Sealed Wednesday, 15 Oct 2008 | 10:03 AM ET
    Genentech Earnings

    On the Genentech third quarter earnings conference call analysts, investors and reporters were hoping to get some color on the status of the Roche play for the rest of DNA it doesn't already own.

  • The Last Word--For Now--On Dendreon Wednesday, 8 Oct 2008 | 10:55 AM ET

    Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.

  • Roche Speaks My Language But Genentech Not So Much Tuesday, 7 Oct 2008 | 11:59 AM ET

    In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.